Research & Development: Page 13
-
Do R&D costs justify the price of drugs? Nope, new study says
A BMJ study found that spending on drug sales vastly outstripped spending on drug development.
By Alexandra Pecci • March 1, 2023 -
As clinical trials face a hiring crunch, here’s how research organizations can pivot
Staffing shortages are causing inefficiencies in clinical trials, but one leading CRO is finding ways to adapt.
By Kelly Bilodeau • Feb. 27, 2023 -
Explore the Trendline➔
Stock via Getty ImagesTrendlineClinical trial diversity
As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.
By PharmaVoice staff -
Q&A // Biotech Spotlight
Cytokinetics looks to muscle into the cardiovascular market
With a scientific platform based on muscle biology, the late-stage biotech is addressing cardiovascular and neuromuscular diseases.
By Taren Grom • Feb. 24, 2023 -
Profile
Tapping into the molecular fountain of youth
Kristen Fortney, CEO of BioAge Labs, wants to improve the human life span by focusing on the human health span.
By Alexandra Pecci • Feb. 22, 2023 -
Podcast
Woman of the Week: Alltrna’s Michelle Werner
The first-time CEO has her sights on addressing thousands of diseases with the company’s tRNA platform.
By Taren Grom • Feb. 22, 2023 -
Why the pharma industry is digging deep in rare disease
The rare disease market is set for major growth in the decade to come, and pharma companies are securing their footholds now.
By Michael Gibney • Feb. 21, 2023 -
Biotechs teeter on unsteady ground in 2023 and some may close shop
A slew of early stage biotechs were forced to shut down last year as the market tanked. Will the trend continue?
By Kelly Bilodeau • Feb. 21, 2023 -
Despite rare disease market growth, pharma leaders see development obstacles ahead
Investment in rare disease research is increasing, but a recent poll of PharmaVoice readers found that roadblocks remain.
By Karissa Waddick • Feb. 17, 2023 -
Q&A // First 90 Days
Pheast’s new CEO on how its ‘don’t eat me’ platform could deliver next-gen precision immunotherapies
Jacopo Leonardi’s latest venture is in the burgeoning field of macrophage inhibitors that could target a wide range of cancers.
By Taren Grom • Feb. 17, 2023 -
Q&A // Biotech Spotlight
Nectin’s Keytruda combo could fill gaps in immuno-oncology’s treatment paradigm
The Israeli biotech just entered into a collaboration with Merck to develop its own checkpoint inhibitor alongside the bestselling cancer treatment.
By Michael Gibney • Feb. 16, 2023 -
Q&A
Managing for resilience: Passage’s ups and downs in gene therapy
After a rocky year, Passage Bio’s CEO is focused on helping the rare disease specialist bounce back.
By Meagan Parrish • Feb. 15, 2023 -
Podcast
Woman of the Week: Bristol Myers Squibb’s Ester Banque
The 30-year veteran is heading up the “transformation” of one of the pharma giant’s most important therapeutic portfolios: hematology.
By Taren Grom • Feb. 15, 2023 -
Profile
For Complement’s CEO, storytelling could be just as critical as data
Dr. Rafiq Hasan has his sights on bringing lessons learned at Bayer to ophthalmology-focused Complement Therapeutics.
By Alexandra Pecci • Feb. 14, 2023 -
The post-COVID outlook for decentralized clinical trials
The COVID-19 pandemic had many pharmas turning to DCTs as a way to keep the clinical wheel turning. Can the industry keep that flexibility going forward?
By Michael Gibney • Feb. 14, 2023 -
Why are there gaps in mental healthcare? Often it’s flawed trial methodology
Sunovion Pharmaceuticals has developed a more precise way to track symptoms that could be broadly adopted across the industry.
By Kelly Bilodeau • Feb. 10, 2023 -
Q&A
Rocket Pharmaceuticals is ready for liftoff in the rare disease space
With two rare disease products on the launch pad for FDA submission in 2023 and a growing pipeline, Rocket is fueled for its next era of growth.
By Taren Grom • Feb. 10, 2023 -
Podcast
Woman of the Week: KaliVir Immunotherapeutics’ Helena Chaye
The triple threat CEO — scientist, lawyer and biotech pro — thinks she’s discovered a key to curing a wide range of cancers.
By Taren Grom • Feb. 8, 2023 -
Profile
The unique playbook of Biohaven’s CEO
Vlad Coric’s offbeat business strategy paid off once with a Pfizer buyout. Can he do it again?
By Meagan Parrish • Feb. 8, 2023 -
Leaps in vax tech — researchers find new ways to tackle old problems like fungal infections and cancer
A growing number of fungal infections has caused a stir in the research community, and new vaccines could be the answer down the road.
By Michael Gibney • Feb. 7, 2023 -
Q&A // First 90 Days
Entact Bio’s CEO is leading the company out of stealth and into a new age of protein enhancement
Victoria Richon’s latest venture is in the burgeoning field of protein-enhancing drugs that could target a range of diseases.
By Kelly Bilodeau • Feb. 6, 2023 -
Q&A // Biotech Spotlight
Astria Therapeutics’ edge in an ultra-rare disease
With positive early phase data, CEO Jill Milne is aiming to bring an improved preventative option to patients with hereditary angioedema.
By Taren Grom • Feb. 1, 2023 -
Podcast
Woman of the Week: Bayer’s Dr. Yesmean Wahdan
The VP of medical affairs and women’s health is focused on an audacious goal to meet the needs of 100 million women globally.
By Taren Grom • Feb. 1, 2023 -
Weight loss drugs: the promise and pitfalls
GLP-1 agonists are dominating the anti-obesity scene — but hurdles remain to their uptake.
By Kelly Bilodeau • Jan. 30, 2023 -
Profile
A biotech CEO’s favorite ‘F’ word
At SFA Therapeutics, patients are the “focus” of Ira Spector’s approach to changing the course of autoimmune disease.
By Taren Grom • Jan. 26, 2023 -
Q&A
Gilead’s commercial chief on why 2023 will be a ‘coming out’ year
With a rapidly expanding oncology pipeline and a new approval in HIV, Johanna Mercier discusses Gilead’s quest to transform.
By Meagan Parrish • Jan. 26, 2023